Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial

被引：1

作者：

Mohr, P. ^{[1
]}

Larkin, J. ^{[2
]}

Paly, V. F. ^{[3
]}

Azocar, A. Remiro ^{[4
]}

Baio, G. ^{[4
]}

Kurt, M. ^{[5
]}

Amadi, A. ^{[6
]}

Rizzo, J. I. ^{[5
]}

Johnson, H. M. ^{[6
]}

Moshyk, A. ^{[5
]}

Kotapati, S. ^{[5
]}

Middleton, M. ^{[7
]}

机构：

[1] Elbe Klinikum Buxtehude, Dept Dermatol, Buxtehude, Germany

[2] Royal Marsden NHS Fdn Trust, Dept Med, London, England

[3] ICON Plc, Hlth Econ Reimbursement & Outcomes, Global HTA, New York, NY USA

[4] UCL, Dept Stat Sci, London, England

[5] Bristol Myers Squibb, Hlth Econ & Outcomes Res, Princeton, NJ USA

[6] Bristol Myers Squibb, Hlth Econ & Outcomes Res, Uxbridge, Middx, England

[7] Univ Oxford, Dept Oncol, Oxford, England

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.1228

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1105P

引用

页码：S747 / S747

页数：1